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ABSTRACT
Background  Histone deacetylase inhibitors (HDACi) 
display potent therapeutic efﬁ  cacy in animal models of 
arthritis and suppress inﬂ  ammatory cytokine production 
in rheumatoid arthritis (RA) synovial macrophages and 
tissue.
Objectives  To determine the molecular mechanisms 
contributing to the suppressive effects of HDACi on RA 
synovial cell activation, using interleukin 6 (IL-6) regulation 
as a model.
Methods  RA ﬁ  broblast-like synoviocytes (FLS) and 
healthy donor macrophages were treated with IL-1β, 
tumour necrosis factor (TNF)α, lipopolysaccharide or 
polyinosinic:polycytidylic acid (poly(I:C)) in the absence 
or presence of the HDACi trichostatin A (TSA) or ITF2357 
(givinostat). IL-6 production and mRNA expression 
was measured by ELISA and quantitative PCR (qPCR), 
respectively. Protein acetylation and the activation of 
intracellular signalling pathways were assessed by 
immunoblotting. The DNA-binding activity of nuclear 
factor κB (NFκB) and activator protein 1 (AP-1) 
components was measured by ELISA-based assays.
Results  HDACi (0.25–1.0 µM) suppressed RA FLS IL-6 
production induced by IL-1β, TNFα and Toll-like receptor 
ligands. Phosphorylation of mitogen-activated protein 
kinases and inhibitor of κBα (IκBα) following IL-1β 
stimulation were unaffected by HDACi, as were AP-1 
composition and binding activity, and c-Jun induction. 
TSA induced a signiﬁ  cant reduction in nuclear retention 
of NFκB in FLS 24 h after IL-1β stimulation, but this did 
not reduce NFκB transcriptional activity or correlate 
temporally with reductions in IL-6 mRNA accumulation. 
HDACi signiﬁ  cantly reduced the stability of IL-6 mRNA in 
FLS and macrophages.
Conclusions  Our study identiﬁ  es a novel, shared 
molecular mechanism by which HDACi can disrupt 
inﬂ  ammatory cytokine production in RA synovial cells, 
namely the promotion of mRNA decay, and suggests 
that targeting HDAC activity may be clinically useful in 
suppressing inﬂ  ammation in RA.
INTRODUCTION
Excessive production of inﬂ  ammatory  media-
tors pivotally contributes to pathology in many 
chronic immune-mediated diseases (IMIDs), 
including rheumatoid arthritis (RA).1 In RA, acti-
vated immune cells inﬁ  ltrating the synovial tissue 
secrete large quantities of tumour necrosis factor 
(TNF)α, interleukin 1 (IL-1), IL-8 and IL-6, among 
other cytokines and chemokines. These secreted 
products, as well as cell–cell contacts, activate 
stromal ﬁ   broblast-like synoviocytes (FLS), which 
are potent effector cells in RA, generating enzymes 
that degrade cartilage and bone, and serving as a 
primary source of inﬂ  ammatory cytokines in the 
synovium.2 3
Production of inﬂ  ammatory cytokines is tightly 
regulated at multiple levels, including activation 
of signalling pathways, induced and epigenetic 
mechanisms regulating transcription factor access 
to gene promoters, post-transcriptional mRNA 
processing and protein secretion. Each of these 
processes can be regulated by reversible protein 
acetylation. Inﬂ   ammatory stimuli activate tran-
scriptional coactivators possessing intrinsic histone 
acetyltransferase (HAT) activity, leading to histone 
acetylation and increased accessibility of gene pro-
moters for transcription.4 Histone deacetylases 
(HDACs), including the ubiquitously expressed 
class I HDACs (HDACs 1–3 and 8) and tissue-re-
stricted class II HDACs (HDACs 4–7, 9, 10), coun-
teract the activity of HATs to terminate ongoing 
transcriptional processes.5
While some studies have indicated that 
decreased expression of HDACs in synovial tis-
sue may contribute to pathology in RA,6 7 analy-
ses of murine and human monocytes revealed that 
HDAC inhibitors (HDACi) are potent anti-inﬂ  am-
matory agents, which suppress lipopolysaccha-
ride (LPS)-induced and TNFα-induced cytokine 
production.8–10 Also, HDACi uniformly amelio-
rate inﬂ  ammation and prevent joint destruction in 
prophylactic and therapeutic protocols in animal 
arthritis models.11–16 These ﬁ  ndings are relevant 
to RA as we have previously demonstrated that 
HDACi suppress IL-6 and TNFα production by 
RA synovial macrophages and synovial tissue 
explants.17 Moreover, RA FLS proliferation and 
survival in vitro is suppressed by HDACi.15 18 19 
The exact mechanisms by which HDACi alleviate 
inﬂ  ammation in acute and chronic inﬂ  ammatory 
diseases remain unclear, but could be related to 
regulation of histone acetylation. Alternatively, 
HDACi may target some 1700 structural and 
signal transduction proteins, many of which are 
relevant to RA, including components of the mito-
gen-activated protein kinase (MAPK) and signal 
transducer and activator of transcription (STAT) 
pathways, transcription factors such as p53, 
nuclear factor κB (NFκB) p65 and c-Jun, as well 
as regulators of mRNA stability, protein degrada-
tion and secretion.20–22 Further understanding of 
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the molecular mechanism(s) contributing to anti-inﬂ  ammatory 
effects of HDACi may facilitate hypothesis-driven decisions 
as to the suitability of HDACi in the treatment of RA, espe-
cially now that one HDACi, ITF2357 (givinostat; Italfarmaco, 
Cinisello Balsamo, Italy), has demonstrated initial clinical efﬁ  -
cacy in the treatment of systemic onset juvenile idiopathic 
arthritis (SOJIA).23 24
Expression of IL-6 in RA synovial tissue strongly correlates 
with disease activity and inﬂ  ammation severity in RA,25 and tar-
geting of IL-6 signalling using tocilizumab, an anti-IL-6 receptor 
monoclonal antibody, demonstrates clinical efﬁ  cacy in RA.26 Here 
we examined the mechanism by which HDACi might suppress 
IL-6 expression in RA FLS and macrophages, assessing effects on 
intracellular signalling pathways leading to IL-6 transcription and 
post-transcriptional regulatory events. We identify inhibition of 
IL-6 mRNA stability as a novel common mechanism by which 
HDACi regulate inﬂ  ammatory gene expression in RA.
MATERIALS AND METHODS
Cell culture and stimulation
FLS were isolated from synovial biopsies of patients with RA 
(n=18) fulﬁ  lling the American College of Rheumatology revised 
criteria for RA,27 cultured as previously described,28 and used 
for experiments between passages 4 and 9, following overnight 
culture in medium containing 1% fetal bovine serum (FBS; 
Invitrogen, Breda, The Netherlands) (see supplementary table 
1 for patient characteristics). Monocytes were isolated from 
buffy coats (Sanquin Reagents, Amsterdam, The Netherlands) 
of healthy donors (HDs) and differentiated into macrophages as 
described previously.17 Cells were treated with medium alone 
or medium containing trichostatin A (TSA) (Sigma-Aldrich, St 
Louis, Missouri, USA) or ITF2357 at the indicated concentra-
tions for 30 min, followed by stimulation with IL-1β (0.2–10 ng/
ml) (R&D Systems, Minneapolis, Minnesota, USA), TNFα (10 
ng/ml) (Biosource International, Camarillo, CA, USA), LPS (1 
μg/ml) or polyinosinic:polycytidylic acid (poly(I:C)) (10 μg/ml) 
(both from Sigma-Aldrich) for up to 24 h.
Measurement of cell viability
RA FLS viability was assessed 24 h post treatment by incubating 
cells with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Sigma-Aldrich) (1 mg/ml) for 2 h, followed by 
solubilisation of cells in acidiﬁ  ed isopropanol solution contain-
ing 0.1% Igepal CA-630 (Sigma-Aldrich) and optical density 
measurement at 590 nm.
Quantitative measurement of IL-6 protein and mRNA expression
IL-6 protein production was measured in cell-free superna-
tants 24 h post stimulation using a PeliKine Compact ELISA kit 
(Sanquin Reagents). mRNA expression in FLS and macrophages 
was assessed by quantitative PCR (qPCR) as described in detail 
in the supplementary methods.
Protein extraction and immunoblotting
For determination of protein acetylation status and signalling 
pathway activation, FLS were left untreated or treated with TSA 
or ITF2357 for 30 min, prior to further incubation in medium 
alone or IL-1β for the time periods indicated in the ﬁ  gure leg-
ends. Protein extraction from whole cell lysates was as previ-
ously described, and nuclear fraction extraction and analysis by 
immunoblotting are described in detail in the supplementary 
methods.17
Measurement of transcription factor DNA-binding and 
transcriptional activity
DNA binding activities of NFκB components p65 and p50, and 
activator protein 1 (AP-1) components p-c-Jun, JunB and JunD in 
FLS nuclear fractions were determined using a TransAM tran-
scription factor ELISA (Active Motif, Carlsbad, California, USA) 
according to the manufacturer’s instructions. NFκB transcrip-
tional activity in FLS was assessed using a recombinant adenovi-
ral vector encoding a NFκB–luciferase reporter. Construction of 
the vector, generation of viral particles, transduction of FLS and 
measurement of luciferase activity are described in detail in the 
supplementary methods.
Statistical analyses
Data are presented as mean±SEM unless otherwise indicated. 
For analysing HDACi treatment dose responses, data sets were 
subjected to an overall Kruskal–Wallis test followed by post hoc 
Dunns’ multiple comparison test, using cells not exposed to 
HDACi as reference controls. In mRNA stability experiments, 
the rate of mRNA degradation over time was determined in each 
experimental condition and area under the curve (AUC) values 
were calculated and compared using the Mann–Whitney U test. 
The Mann–Whitney U test was used for all other comparisons. 
p values ≤0.05 were considered statistically signiﬁ  cant.
RESULTS
HDACi suppress RA FLS IL-6 production
Multiple HDACi block IL-6 production by monocytes and mac-
rophages derived from HD, as well as synovial macrophages 
and tissue from patients with RA.9 10 17 To determine if HDACi 
could also inhibit RA FLS IL-6 production, we treated RA FLS 
with increasing concentrations of TSA or ITF2357 prior to stim-
ulation with agonists found in RA synovial tissue. Both HDACi 
dose-dependently suppressed IL-6 production induced by IL-1β. 
TSA achieved 50% inhibition of IL-6 production at 0.25 μM and 
more than 80% at 1 μM (p<0.001). A trend towards reduced 
IL-6 production was observed at clinically relevant concentra-
tions of ITF2357 (0.25 μM), reaching 80% inhibition at 1 μM 
(p<0.01) (ﬁ  gure 1A). HDACi also suppressed IL-6 production in 
response to TNFα and the Toll-like receptor (TLR) ligands LPS 
and poly(I:C) by 50% to 80% (p<0.05) (ﬁ  gure 1B). HDACi sup-
pression of IL-6 production could not be attributed to changes 
in FLS viability following exposure to HDACi, as measured by 
MTT reduction (ﬁ  gure 1C). As previously observed in RA mac-
rophages, TSA suppressed the induction of IL-6 mRNA in FLS.17 
1 μM TSA reduced IL-1β-induced IL-6 mRNA accumulation by 
70% (p<0.01) (ﬁ  gure 2A), while 0.25 μM ITF2357 reached 45% 
inhibition (p<0.01) (ﬁ   gure 2B). ITF2357 blocked IL-6 mRNA 
accumulation in a concentration-dependent manner regardless 
of the dose of IL-1β used (ﬁ  gure 2C).
Suppression of IL-6 production by HDACi does not require 
epigenetic induction of transcriptional repressors
To determine if inhibition of IL-6 transcription by HDACi might 
result from induced expression of transcriptional corepressors 
or negative regulatory signalling components, we examined 
histone 3 (H3) and H4 acetylation following HDACi treatment. 
HDACi induced acetylation of H3 and H4, as well as a protein of 
52 kDa (identiﬁ  ed as tubulin, data not shown) (ﬁ  gure 3A,B). No 
global changes in FLS protein acetylation status could be detected 
in response to IL-1β, TNFα or LPS alone (ﬁ  gure 3B). TSA and 
ITF2357 both induced H3, H4 and total cellular protein acetyla-
tion within 15 min of HDACi exposure (ﬁ  gure 3A), consistent 
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Figure 1  Histone deacetylase inhibitors (HDACi) suppress interleukin 6 (IL-6) production by rheumatoid arthritis ﬁ  broblast-like synoviocytes (FLS) 
without affecting cell viability. A. FLS were stimulated with 10 ng/ml of IL-1β alone or in the presence of increasing concentrations of trichostatin A 
(TSA) or ITF2357 for 24 h (n=6–10). B. Alternatively, cells were left untreated or pre-exposed to 1 µM TSA followed by 24 h stimulation with IL-1β 
(10 ng/ml), tumour necrosis factor (TNF)α (10 ng/ml), lipopolysaccharide (1 µg/ml) or polyinosinic:polycytidylic acid (poly(I:C)) (10 µg/ml) (n=4). IL-6 
levels in cell-free tissue culture supernatants were determined by ELISA. Results, presented as mean±SEM IL-6 concentration, were either subjected 
to the Kruskal–Wallis test followed by Dunns’ multiple comparison analysis with cells not treated with HDACi used as reference controls (A), or to 
the Mann–Whitney U test (B). *p<0.05; **p<0.01; ***p<0.001. C. Viability of cells after 24 h stimulation with IL-1β (10 ng/ml) in the presence or 
absence of increasing doses of TSA or ITF2357 was assessed by measurement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
reduction (n=5). Values representing changes in MTT processing are shown as mean±SEM optical density at 590 nm.
subsequent rapid induction of c-Jun expression are essential pre-
requisites for optimal IL-6 gene transcription, and are sensitive 
to acetylation.30 31 However, similarly to p38 and ERK, IL-1β-
stimulated JNK phosphorylation in FLS was unaffected by TSA 
(ﬁ  gure 4B). Also, IL-1β induced a transient ﬁ  vefold increase of 
c-Jun mRNA levels which was unaffected by TSA (ﬁ  gure 4C). 
Stimulation with IL-1β caused a 2.5-fold increase in p-c-Jun DNA 
binding compared to unstimulated FLS (ﬁ  gure 4D). However, 
FLS exposure to TSA did not suppress the induction of c-Jun 
binding activity (ﬁ  gure 4D) and had no inﬂ  uence on DNA bind-
ing of Jun family members JunB and JunD (data not shown). 
Collectively, these results suggest that HDACi-dependent IL-6 
suppression in RA FLS is not mediated by direct regulation of 
MAPK and AP-1 signalling pathways.
HDACi modulate NFκB signalling in RA FLS
NFκB signalling makes pivotal contributions to the induction of 
IL-6 expression, and the activity as well as nuclear retention of 
NFκB subunits is tightly regulated by reversible acetylation.32 In 
initial experiments, we found that TSA treatment had no effect 
on the magnitude or kinetics of inhibitor of κBα (IκBα) phos-
phorylation or degradation in RA FLS (ﬁ  gure 5A). To examine 
the inﬂ  uence of HDACi on the temporal regulation of NFκB 
nuclear retention, FLS were cultured in the absence or presence 
of TSA and then stimulated with medium alone or IL-1β, and 
with the possibility that histone hyperacetylation might lead 
to transcriptional induction of repressors of IL-6 transcription. 
However, in the absence or presence of the protein translation 
inhibitor cycloheximide (CHX), TSA suppressed IL-1β-induced 
IL-6 mRNA accumulation in FLS (p<0.05) (ﬁ  gure 3C). The failure 
of CHX to rescue IL-6 mRNA accumulation suggested that de 
novo synthesis of a repressor protein is not required for HDACi 
suppression of IL-6 in RA FLS.
HDACi fail to affect MAPK signalling and AP-1 
activation in RA FLS
Activation of MAPK and NFκB signalling pathways, leading 
to transcriptional activation of NFκB and AP-1, are required 
for IL-1β-induced IL-6 production, and can be modulated by 
reversible acetylation.20 29 We analysed the effects of TSA on 
the phosphorylation status of p38 and extracellular signal-regu-
lated kinase (ERK) MAPK in RA FLS by immunoblotting. IL-1β 
induced rapid phosphorylation of p38 and ERK, which peaked 
30 min post stimulation. TSA treatment affected neither phos-
phorylation levels, nor temporal regulation of p38 and ERK 
activation (ﬁ  gure 4A), indicating that HDACi blockade of RA 
FLS IL-6 production is not mediated by suppression of MAPK 
signalling.
Phosphorylation of c-Jun N-terminal kinase (JNK), activation 
of the c-Jun component of the AP-1 transcription factor and 
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nuclear accumulation of p50 and p65 NFκB subunits assessed 
by immunoblotting. TSA had little effect on nuclear p50 and 
p65 in the absence of inﬂ  ammatory stimulation, but slightly 
increased the amounts of both proteins 1 h after IL-1β stimu-
lation. However, nuclear retention of these subunits 24 h post 
stimulation was strongly reduced (ﬁ  gure 5B). In DNA-binding 
assays we observed a trend towards elevated p50 and p65 bind-
ing 1 h after IL-1β stimulation in the presence of TSA, while a 
signiﬁ  cant reduction of DNA binding was observed only after 
24 h (ﬁ  gure 5C). To determine if p65 retained transcriptional 
activity in the presence of TSA, we cotransduced RA FLS with 
adenoviral vectors encoding 4×NFκB-minimal promoter (MLP)-
luciferase reporter, and evaluated the effects of TSA on luciferase 
enzymatic activity. TSA did not inhibit, and clearly increased, 
the transcriptional activity of NFκB early after stimulation with 
IL-1β (ﬁ  gure 5D). Together, these ﬁ  ndings indicate that HDACi-
Figure 2  Histone deacetylase inhibitors reduce interleukin 6 (IL-6) mRNA accumulation in rheumatoid arthritis ﬁ  broblast-like synoviocytes (FLS). 
FLS were left unstimulated, or were stimulated with IL-1β (10 ng/ml) with or without 1 µM trichostatin A (A), or with IL-1β (1 ng/ml) in the presence 
or absence of 0.25 µM ITF2357 (B) for 4 h, total RNA was extracted, reverse transcribed and IL-6 mRNA accumulation analysed by quantitative PCR 
(qPCR). Results are presented as mean±SEM IL-6 expression relative to 18S of ﬁ  ve independent experiments. **p<0.01, Mann–Whitney U test. 
Alternatively (C), FLS (n=3) were stimulated as above with increasing concentrations of IL-1β (0.2–10 ng/ml) in the absence (med) or presence of 
increasing concentrations of ITF2357 (0.1–1.0 µM) and IL-6 mRNA expression assessed as in (A) and (B).
Figure 3  New protein synthesis is not required for ﬁ  broblast-like synoviocyte (FLS) interleukin 6 (IL-6) suppression by histone deacetylase inhibitors. 
A. FLS were left untreated (med) or were treated with trichostatin A (TSA) (1 µM) or ITF2357 (1 µM) for the indicated time (min). Protein extracts 
were prepared and analysed by immunoblotting for acetylated lysine (Ac-Lys), Ac-H3, H3, Ac-H4, H4 and tubulin (Tub) content. B. FLS were left 
unstimulated in medium (med) or were stimulated with IL-1β (10 ng/ml), tumour necrosis factor (TNF)α (10 ng/ml) or lipopolysaccharide (1 µg/ml), 
lysed and examined by immunoblotting with antibodies recognising Ac-Lys, Ac-H3, H3, Ac-H4, H4 and Tub. FLS treated with 1 µM TSA for 4 h were 
used as a positive control. Results are representative of three independent experiments. C. FLS were left untreated or were treated with IL-1β (10 
ng/ml) with or without 1 µM TSA for 4 h. To block protein translation, cells were preincubated with 1 µg/ml cycloheximide (CHX) for 30 min prior to 
stimulation. IL-6 mRNA levels were assessed by quantitative PCR (qPCR) and presented as relative IL-6 expression ±SEM (n=4). *p<0.05, Mann–
Whitney U test.
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induced suppression of IL-6 mRNA, detectable 4 h after inﬂ  am-
matory stimulation, precedes inhibitory effects of HDACi on 
p50 and p65 DNA binding and nuclear retention.
HDACi modulate IL-6 mRNA stability in RA FLS and HD 
macrophages
To gain more insight into the kinetics of IL-6 suppression by 
HDACi in RA FLS, we treated the cells with IL-1β for 1–8 h 
with or without TSA, and measured changes in IL-6 mRNA lev-
els over time. IL-1β induced a 20-fold increase in IL-6 mRNA 
levels within 1 h, which remained stable until 4 h before further 
increasing. TSA failed to affect IL-6 mRNA accumulation 1 h 
after stimulation, but a strong reduction was observed at 4 h and 
became more pronounced at 8 h (p<0.05) (ﬁ  gure 6A). As we had 
previously ruled out a need for de novo repressor synthesis in 
HDACi-mediated IL-6 suppression, we examined if differences 
might be attributable to effects on mRNA stability. FLS were 
stimulated with IL-1β for 4 h in the presence or absence of TSA, 
and after inhibiting transcription with actinomycin D (ActD), 
we analysed time-dependent IL-6 mRNA decay. Accelerated 
degradation of IL-6 mRNA in TSA-treated FLS was detectable 
within 1 h of ActD treatment, becoming more pronounced at 
later time points (p<0.05 for AUC) (ﬁ  gure 6B). Similar effects 
were observed in the presence of 0.25 μM ITF2357 (ﬁ  gure 6C). 
The presence of TSA also signiﬁ  cantly accelerated IL-6 mRNA 
decay in LPS-stimulated macrophages (ﬁ  gure 6D).17 Together, 
these results indicate that modulation of mRNA stability is a 
common mechanism by which IL-6 production is suppressed by 
HDACi in macrophages and RA FLS.
DISCUSSION
IL-6 acts pleiotropically to induce acute-phase protein synthe-
sis, stimulate B cell antibody production, modulate T helper 17 
(Th17) and cytotoxic T cell differentiation, activate endothelial 
cells and induce osteoclast differentiation. Under physiological 
conditions, proinﬂ  ammatory and anti-inﬂ  ammatory effects of 
IL-6 contribute to an effective but self-limiting acute immune 
response, but in RA and other IMIDs, excessive IL-6 produc-
tion leads to deregulation of the immune system and pathol-
ogy. Despite the dual role of IL-6 in regulating inﬂ  ammation, 
targeting of the IL-6 receptor has shown strong clinical beneﬁ  ts 
in RA.26 However, since a substantial fraction of patients with 
RA remain non-responsive to currently available anticytokine 
therapies, there is growing interest in identifying novel thera-
peutic targets which could suppress inﬂ  ammatory  cytokine 
production, such as HDACi. Pharmacological inhibition of 
HDAC activity has shown anti-inﬂ   ammatory effects in ani-
mal arthritis models,11–16 and synovial macrophages and tissue 
explants from patients with RA.17 Here, we show that HDACi 
reduce RA FLS IL-6 production induced by cytokines and TLR 
ligands, and identify modulation of IL-6 mRNA stability as a 
primary molecular mechanism contributing to this effect in FLS 
and macrophages.
RA FLS treatment with HDACi, as previously observed with 
RA synovial macrophages,17 rapidly induced acetylation of his-
tone and non-histone proteins, raising the possibility that HDACi-
induced expression of transcription corepressors might explain 
the suppressive effects of HDACi on IL-6 production. However, 
treatment of cells with CHX, to prevent translation of putative 
repressors, failed to rescue IL-6 production in the presence of 
HDACi. Consistent with this, even though HDACi induce H4 
hyperacetylation in the IL-6 promoter region in murine bone 
marrow-derived macrophages, IL-6 production is downregulated, 
Figure 4  Histone deacetylase inhibitors (HDACi) fail to affect mitogen-
activated protein kinase (MAPK) signalling and activator protein 1 (AP-1) 
activation in rheumatoid arthritis ﬁ  broblast-like synoviocytes (FLS). 
A. FLS were left unstimulated (med) or were stimulated with 10 ng/
ml of interleukin 1β (IL-1β) for the indicated time (min) in the presence 
or absence of 1 µM trichostatin A (TSA), proteins were extracted and 
MAPK activation analysed by immunoblotting with antibodies speciﬁ  c 
for phospho(p)-p38, p38, p-extracellular signal regulated kinase (ERK), 
ERK and tubulin (Tub). Anti-acetylated lysine (Ac-Lys) antibody was 
used to conﬁ  rm TSA HDACi activity in this experiment. B. FLS were 
subjected to the same treatment as in (A) and c-Jun N-terminal kinase 
(JNK) activation determined in cellular lysates by immunoblotting for 
p-JNK and Tub content. C. HDACi do not modulate c-Jun induction by an 
inﬂ  ammatory stimulus. FLS were stimulated with medium alone (med) 
or with IL-1β (10 ng/ml) with or without 1 µM TSA for 1 h or 4 h, total 
RNA was reverse transcribed, and changes in c-Jun mRNA levels were 
determined by quantitative PCR (qPCR). Results of four independent 
experiments are shown as relative expression ±SEM. D. HDACi have 
no effect on c-Jun DNA binding activity. FLS were left unstimulated 
in medium (med) or were treated with IL-1β (10 ng/ml) for 4 h in the 
presence or absence of 1 µM TSA, nuclear fractions were extracted and 
levels of active p-c-Jun were determined using an ELISA-based DNA-
binding assay. Data represent the mean±SEM optical density at 450 nm 
for ﬁ  ve independent experiments.
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Figure 5  Histone deacetylase inhibitors (HDACi) increase nuclear factor κB (NFκB) transcriptional activity early after stimulation, but inhibit NFκB 
nuclear retention at later time points. A. Fibroblast-like synoviocytes (FLS) were left untreated (med) or were treated with interleukin 1β (IL-1β) (10 ng/
ml) for 5–120 min in the presence or absence of 1 µM trichostatin A (TSA), and total cell lysates examined by immunoblotting for phospho(p)- inhibitor 
of κBα (IκBα) and tubulin (Tub) content. Alternatively, FLS were cultured in the presence or absence of 1 µM TSA and then stimulated with medium 
alone or 10 ng/ml of IL-1β for 1 h, 4 h or 24 h. Nuclear extracts (n=4) were either separated by electrophoresis and nuclear accumulation of NFκB 
subunits analysed by immunoblotting with antibodies recognising p50, p65 and histone 3 (H3) (B), or were used for determination of p50 and p65 
DNA-biding activities by an ELISA-based DNA biding assay (C). Values representing changes in p50 (left panel) and p65 (right panel) are shown as 
mean±SEM optical density at 450 nm. *p<0.05; **p<0.01, Mann–Whitney U test. D. FLS were cotransduced with a 4×NFκB-minimal promoter 
(MLP)-luciferase and control cytomegalovirus β-galactosidase (CMV-β-gal) adenoviral vectors. At 48 h after transduction, cells were serum-starved 
for 24 h and then left untreated or stimulated with IL-1β (10 ng/ml) with or without 1 µM TSA for 2 h, 4 h or 8 h. Cellular lysates were prepared and the 
luciferase (Luc) and β-gal enzymatic activities determined by luminometry and spectrophotometry, respectively. Data are presented as relative luciferase 
activity normalised to β-gal activity ±SD and a representative of two independent experiments is shown.
arguing against involvement of changes in histone acetylation sta-
tus in HDACi regulation of IL-6.33 Surprisingly, we also found little 
evidence supporting a role for HDACi in modulating acute signal 
transduction events downstream of IL-1β stimulation. Previous 
reports have indicated that HDACi might regulate inﬂ  ammatory 
gene expression via blockade of MAPK signalling,34 suppression 
of c-Jun induction and activation,31 or reduction of NFκB nuclear 
retention.19 In murine macrophages, HDACi treatment causes 
acetylation and activation of MAPK phosphatase-1 which pre-
vents p38 phosphorylation, ultimately leading to inhibition of 
TLR signalling.34 However, we observed no effect of TSA on 
IL-1β-induced activation of p38, ERK and JNK MAPKs, c-Jun gene 
induction, or DNA binding activity of Jun family members. Our 
negative results highlight the difﬁ  culties of extrapolating effects 
of HDACi in various cell types to primary cells from RA synovial 
tissue in the absence of formal studies.
NFκΒ signalling is complexly regulated by reversible acetyla-
tion, as p65 can be acetylated on at least ﬁ  ve unique lysine resi-
dues, each having a distinct effect on p65 function. Acetylation at 
Lys221 promotes p65 dissociation from IκBα and nuclear import, 
while acetylation at 310 enhances p65 transcriptional activity.35 
36 Alternatively, p65 acetylation at Lys122 and Lys123 decreases 
DNA binding afﬁ  nity, enhances IκBα association and promotes 
nuclear export.37 We observe a similarly complex regulation in 
RA FLS, as p65 nuclear import, DNA binding activity and tran-
scriptional capacity are all enhanced by HDACi in the initial 
hours following IL-1β stimulation. However, HDACi promote 
dissociation from DNA and nuclear export at later time points, 
consistent with recent observations in an SV40 Tag-transformed 
RA FLS cell line.19 The changes we observe in NFκB activity are 
consistent with temporal acetylation of NFκB at distinct regula-
tory sites, but direct studies are needed to address this possibil-
ity. However, the kinetics of alterations in NFκB activity cannot 
explain the acute suppression of IL-1β-induced IL-6 production 
by HDACi, but may confer a protective effect in the face of 
chronic inﬂ  ammatory stimulation.
While many of the HDACi effects on cellular activation have 
been attributed to epigenetic regulation or inﬂ  uences on signal 
transduction, studies in cancer biology have provided initial 
evidence that these compounds can modulate gene expression 
via regulation of mRNA stability.38–40 We observe a similar and 
shared mechanism of action in the suppression of IL-6 produc-
tion in macrophages and RA FLS. mRNA stability is regulated by 
hundreds of gene products, some of which have been identiﬁ  ed 
as functionally associated with HDACs.41 42 Selectivity is also 
observed in mRNAs targeted by these proteins as, for example, 
Zc3h12 RNAse speciﬁ   cally regulates IL-6 mRNA stability.43 
Alternatively, as observed in cancer biology studies, HDACi 
might differentially modulate microRNA (miR) expression.44 
IL-6-speciﬁ  c miRs have yet to be identiﬁ  ed, but the expression of 
several miRs associated with inﬂ  ammatory responses is altered 
in RA FLS and synovial tissue.45 Future studies will be needed 
to elucidate how HDACi enhance IL-6 mRNA degradation, and 
test how globally this mechanism regulates gene expression 
in RA synovial tissue. Preliminary experiments indicate that 
HDACi might also regulate FLS production of IL-8 and matrix 
metalloproteinase 1 without affecting mRNA stability (data not 
shown), indicating additional mechanisms by which HDACi 
modulate gene expression in RA FLS. Intriguingly, HDACi can 
accelerate decay of DNA methyltransferase 3B mRNA in human 
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endometrial cells, raising the possibility that HDAC-dependent 
mRNA destablisation might regulate inﬂ  ammatory gene expres-
sion through crosstalk with epigenetic DNA methylation 
pathways.46 The results presented here provide the ﬁ  rst mecha-
nistic evidence by which HDACi might suppress inﬂ  ammatory 
cytokine production in RA, and, together with the initial proof 
of principle that has recently been obtained in SOJIA,23 24 sup-
port the notion that HDACi may represent a novel therapeutic 
approach for the treatment of RA.
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